TMB

AnswerNet Launches TextMyBusiness to Enable Companies to Communicate Via Text On Their Business Phone Numbers

Retrieved on: 
Friday, March 1, 2024

TextMyBusiness is designed to move business text communications off of personal employee cell numbers and on to business numbers owned and controlled by the business without losing the immediacy of text communications.

Key Points: 
  • TextMyBusiness is designed to move business text communications off of personal employee cell numbers and on to business numbers owned and controlled by the business without losing the immediacy of text communications.
  • TextMyBusiness helps companies text-enable their business phone numbers to transform how they connect with customers.
  • "Our clients and all businesses have struggled separating their business text communications from their employees' personal cell phone numbers," said Gary Pudles, President and CEO of AnswerNet.
  • "Businesses need to communicate via text on business software and on mobile devices where the communications can be managed and saved by the business.

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Retrieved on: 
Friday, January 19, 2024

LOS ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA. 

Key Points: 
  • LOS ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    In a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers
    Most TSC1 and/or TSC2 inactivating alterations in liver and pancreatic cancers occurred in the context of low TMB and MSS tumors; whereas increased TMB and MSI signatures were enriched in colorectal cancer with TSC1 and/or TSC2 alterations
    Limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data.
  • More research is needed to understand the clinical and prognostic implications of these data
    Aadi is also presenting Trials-in-Progress (TiP) posters from its PRECISION 1 and NET clinical studies.
  • Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
    Title: "A phase 2, study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lunch, or pancreas"
    Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Powered by Its Industry-Leading Comprehensive Multi-Modal Database, Caris Life Sciences to Showcase Research at ASCO Gastrointestinal Cancers Symposium 2024

Retrieved on: 
Wednesday, January 17, 2024

IRVING, Texas, Jan. 17, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 11 studies across six solid tumor types at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco. The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.  

Key Points: 
  • "We are proud to again present a wide array of precision oncology research at this year's ASCO GI.
  • Strikingly, patients with early-onset CCA experience better outcomes from immunotherapy even though immune-oncology-relevant markers like MSI and TMB favors average-onset CCA.
  • Two posters use EGFRi-treated CRC samples from the Caris multi-modal database to explore two promising possibilities: APC mutation status and CTX sensitivity score (CTX-S).
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Retrieved on: 
Tuesday, January 16, 2024

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.
  • Matching patients to their optimal cancer therapy requires a testing platform that can accurately report a broader range of clinically actionable genomic alterations.
  • Coverage for NeXT DX was extended effective August 29, 2023, under the Palmetto GBA MolDx program foundational Local Coverage Determination (LCD) L38119 (“Next-Generation Sequencing for Solid Tumors”).
  • Personalis estimates that approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare.

Rockland Launches Impurity Detection Kit for Accurate Measurement of Nuclease Across a Spectrum of Therapeutic Manufacturing Methods

Retrieved on: 
Thursday, January 11, 2024

LIMERICK, Pa., Jan. 11, 2024 /PRNewswire/ -- For over 60 years, Rockland has been providing antibodies, assays, and supporting reagents to accurately reflect the quality of biopharmaceutical products from early- to late-stage bioprocessing. Rockland is a leading expert in antibody and immunoassay development, delivering high coverage and sensitivity against residual contaminants at any stage of development and manufacturing.

Key Points: 
  • Rockland is a leading expert in antibody and immunoassay development, delivering high coverage and sensitivity against residual contaminants at any stage of development and manufacturing.
  • To meet quality and safety standards, it is essential to ensure the absence of such impurities for safe, stable, and effective products.
  • Terri Poole, Chief Commercial Officer, adds, "Delivering this nuclease kit is an example of Rockland's on-going commitment to provide high quality products that build on our growing portfolio of impurity detection tools for bioprocessing.
  • Unwavering quality combined with our ability to consistently meet supply demands makes Rockland the clear choice for many biopharmaceutical companies."

Independent Streaming Alliance (ISA) Announces New Members

Retrieved on: 
Tuesday, January 9, 2024

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- The Independent Streaming Alliance (ISA) announced today its newest members, FilmRise, Gusto TV, Gunpowder & Sky, DangerTV, and Graham Media. The new members join Chicken Soup for the Soul Entertainment, Cineverse, Future Today, kweliTV, Revry, The E.W. Scripps Company, Tastemade, TMB (Trusted Media Brands), and Vevo who together founded the ISA in June 2023.

Key Points: 
  • NEW YORK, Jan. 9, 2024 /PRNewswire/ -- The Independent Streaming Alliance (ISA) announced today its newest members, FilmRise, Gusto TV, Gunpowder & Sky, DangerTV, and Graham Media.
  • The Independent Streaming Alliance (ISA) is an industry forum made up of independent streaming providers focused on working collaboratively with a broad range of external stakeholders, including platforms, advertisers, regulators, and other industry participants, to address the key challenges facing our membership and the CTV industry.
  • "Each new member delivers unique content offerings and illustrates the value and importance of independent content creators to its millions of viewers, which is a primary objective of the Independent Streaming Alliance."
  • The ISA will continue to recruit members across the spectrum of independent ad-supported video streaming services distributed on televisions and other connected devices.

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

Retrieved on: 
Wednesday, December 20, 2023

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).

Key Points: 
  • SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).
  • The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.
  • Built on DNAnexus, a leading enterprise Precision Health platform, the MCRR provides a secure and easy-to-use interface for scientific data analysis, collaboration, and discovery.
  • Myriad is accepting research concept forms from individuals and institutions seeking to undertake research projects.

Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment

Retrieved on: 
Tuesday, December 5, 2023

It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.

Key Points: 
  • It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.
  • This may also explain why clonal neoantigen targeting immunotherapies like Gradalis’ Vigil have shown longer-term overall survival benefits in a randomized controlled trial of patients with solid tumors.
  • Clonal mutations expressed on the cancer surface provide a distinguishing difference between cancer cells and normal non-cancer cells.
  • Emerging research shows that targeting clonal mutations may be critical in achieving a durable clinical benefit,” stated John Nemunaitis, MD, Chief Scientific Officer of Gradalis and co-author of the paper.

People Are Awesome Counts Down the Top Moments of 2023

Retrieved on: 
Tuesday, December 19, 2023

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- People Are Awesome , the TMB -owned streaming channel that shines a spotlight on ordinary people doing extraordinary things, have released their top 5 clips of the year.

Key Points: 
  • NEW YORK, Dec. 19, 2023 /PRNewswire/ -- People Are Awesome , the TMB -owned streaming channel that shines a spotlight on ordinary people doing extraordinary things, have released their top 5 clips of the year.
  • From jaw dropping gymnastics to breathtaking views, and so much more -  the PAA team are crowning the most awesome videos of the year from their vast library of user generated content submitted from people around the world.
  • The #1 clip stunned our viewers as a soccer ball juggler performs tricks while simultaneously ski jumping in a video you have to see to believe.
  • You can see the countdown to #1 here and catch the, Season of Awesome Marathon December 24th through January 1st on the People Are Awesome channel which streams on top platforms including  fubo, LG Channels, philo, Plex, Redbox, Samsung TV Plus, Sling Freestream, Rakuten TV, redbox, The Roku Channel, Tivo, xfinity,  XUMO and out of home on Atmosphere TV.

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on: 
Friday, November 17, 2023

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points: 
  • Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
  • (Photo: Business Wire)
    Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
  • Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
  • "We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.